These pathways are frequently dysregulated via the overexpression of EGFR in many malignant tumors, including colorectal, lung, and breast cancers, brain tumors, head and neck cancers, pancreatic, kidney, and prostate cancers, and ovarian, bladder, and oral cancers (11). Here, EGFR is linked to cancer.